Global Partnerships
Bring Xtagen™ to Your Market
Xtagen™ is a next-generation inflammation therapy developed in Australia and powered by Abagen™ — a patented marine peptide complex with clinically validated multi-pathway action.
As we expand into new regions, we are offering select, territory-wise exclusivity for the right partners.
If you are interested in introducing Xtagen™ in your country, we invite you to get in touch.
Why Xtagen™?
Clinically Validated Innovation
Xtagen™ is designed to modulate IL-6, TNF-α, MAPK, and oxidative pathways — offering broad-spectrum support for inflammation and joint health.
Patented, Science-Driven
Powered by Abagen™, a protected marine peptide matrix, Xtagen™ represents a new class of natural-origin therapeutics with a strong scientific foundation.
Territorial Exclusivity
We offer exclusive rights to distributors in defined markets, ensuring clear, non-competing channel strategies.
End-to-End Support
From scientific content to branding and regulatory assistance — we support our partners at every step.
Interested in Partnering?
Please visit our Contact Page to get in touch with the Xtagen™ team.
We look forward to exploring a potential collaboration.
